15,619 Shares in Celcuity, Inc. $CELC Acquired by Tema Etfs LLC

Key Points

• Tema Etfs LLC has acquired a new position in Celcuity, Inc., purchasing 15,619 shares valued at approximately $158,000 during the first quarter of 2023.
• Insider transactions were noted as Director David Dalvey sold 100,000 shares at an average price of $43.98, reducing his position by 44.44%.
• Analysts have mixed opinions on Celcuity, with some raising target prices; however, the stock's average target price currently stands at $56.50 with a consensus "buy" rating.

Tema Etfs LLC bought a new stake in Celcuity, Inc. (NASDAQ:CELC - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 15,619 shares of the company's stock, valued at approximately $158,000.

Other large investors also recently made changes to their positions in the company. Baker BROS. Advisors LP grew its stake in shares of Celcuity by 42.9% in the 4th quarter. Baker BROS. Advisors LP now owns 2,678,553 shares of the company's stock valued at $35,062,000 after buying an additional 803,575 shares during the period. Ameriprise Financial Inc. grew its stake in shares of Celcuity by 45.9% in the 4th quarter. Ameriprise Financial Inc. now owns 447,171 shares of the company's stock valued at $5,853,000 after buying an additional 140,642 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Celcuity by 16.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company's stock valued at $258,000 after buying an additional 2,756 shares during the period. Bank of America Corp DE grew its stake in shares of Celcuity by 3.9% in the 4th quarter. Bank of America Corp DE now owns 288,259 shares of the company's stock valued at $3,773,000 after buying an additional 10,907 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of Celcuity by 8.9% in the 1st quarter. Rhumbline Advisers now owns 42,194 shares of the company's stock valued at $427,000 after buying an additional 3,439 shares during the period. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Stock Performance

Shares of Celcuity stock traded up $0.05 during mid-day trading on Wednesday, hitting $53.63. 103,923 shares of the stock were exchanged, compared to its average volume of 600,613. Celcuity, Inc. has a 12 month low of $7.57 and a 12 month high of $55.44. The company has a 50-day simple moving average of $31.76 and a 200 day simple moving average of $18.01. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The company has a market capitalization of $2.28 billion, a P/E ratio of -15.54 and a beta of 0.72.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.14). Sell-side analysts anticipate that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CELC has been the topic of several recent research reports. Leerink Partners raised their price target on shares of Celcuity from $28.00 to $60.00 and gave the company an "outperform" rating in a research report on Monday, July 28th. Stifel Nicolaus initiated coverage on shares of Celcuity in a research report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price target on the stock. HC Wainwright raised their price target on shares of Celcuity from $50.00 to $66.00 and gave the company a "buy" rating in a research report on Monday, August 18th. Finally, Needham & Company LLC dropped their price target on shares of Celcuity from $74.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $56.50.

Insider Activity at Celcuity

In related news, Director David Dalvey sold 100,000 shares of Celcuity stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the sale, the director owned 125,000 shares of the company's stock, valued at approximately $5,497,500. The trade was a 44.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 15.77% of the company's stock.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.